Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)

The goal of this Funding Opportunity Announcement (FOA) is to encourage research to explore mechanisms of inflammasome activation, humoral immune reaction and potential antibody-mediated enhancement, and their link to immune functions in people with HIV and substance use disorders (SUDs). This FOA supports studies to either (1) elucidate the mechanisms of inflammasomes in virus and drug-induced immune activation, or (2) identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among individuals with SUD. Success of these projects may lead to development of novel therapies that target inflammasome activation or suppression to treat neuroinflammation and immune dysregulation in people with HIV.

AIDS Deadline: 3/16/2023

Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. The FOA will support technology transfer, preclinical immunogenicity and optimization studies, process development, analytical assay development, qualification, validation, testing, small scale pilot or engineering runs, CGMP manufacture in partnership with Pharma/Biotech/Contract Manufacturing Organizations (CMO), quality assurance/quality control oversight, fill-finish activities, product release and storage, generation of reference standard, drug substance and drug product stability testing programs, Investigational New Drug (IND)-enabling studies, and regulatory submission preparation.

AIDS Deadline: 3/15/2023

Dangers and Opportunities of Technology: Perspectives from the Humanities

Technology has had an enormous impact on modern society, affecting how we work, communicate, learn, engage in the political process, and live. The relationship between technology and culture continues to have dramatic impacts, both positive and negative, on our health, the environment, our social interactions, our government, cultural and educational institutions, the arts, and nearly all other aspects of life.

Deadline: 3/15/2023

Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01)

The Office of Research Infrastructure Programs (ORIP) encourages research project grant applications aimed at developing and implementing broadly applicable technologies, tools, and resources for validating animal models and enhancing rigor, reproducibility, and translatability of animal research. Research projects submitted under this Funding Opportunity Announcement (FOA) should be hypothesis driven with strong preliminary data. Proposed studies, models, resources, or technologies under this FOA must either address research interests of multiple NIH Institutes and Centers (ICs), explore multiple organ systems, or be applicable to diseases and processes that impact multiple organ systems in order to align with ORIP’s NIH-wide mission and programs.

Deadline: 12/22/2022

Integrative Strategies for Understanding Neural and Cognitive Systems (NCS)

The complexities of brain and behavior pose fundamental questions in many areas of science and engineering, drawing intense interest across a broad spectrum of disciplinary perspectives while eluding explanation by any one of them. Rapid advances within and across disciplines are leading to an increasingly interwoven fabric of theories, models, empirical methods and findings, and educational approaches, opening new opportunities to understand complex aspects of neural and cognitive systems through integrative multidisciplinary approaches.

Letter of Intent: 12/15/2022

Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) will support projects that investigate the effects of addictive substances on developmental trajectories of molecularly-defined central nervous system (CNS) cells and circuits. Emphasis is on carrying out systematic and highly granular quantitative characterizations of the impact of in utero and/or postnatal substance exposure on the numbers, spatial distribution and connectivity of molecularly-defined cells, across whole brains or within distributed circuits of clinical relevance. The ultimate goals of the program are to identify critical developmental windows and cellular mechanisms mediating the protracted developmental impact of addictive substances, and to inform clinical practice, by complementing the data from human longitudinal neuroimaging studies such as the HEALthy Brain and Child Development (HBCD) Study and the Adolescent Brain Cognative Development (ABCD) Study.

Deadline: 2/2/2023

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed)

The purpose of this FOA is to solicit applications for Liquid Biopsy Research Laboratories (LBRLs), one of the two components of the Precompetitive Collaboration on Liquid Biopsy for Early-Cancer Assessment Consortium (LBC). LBC is an Academic-Industrial Partnership program to develop and validate liquid biopsy technologies for early-cancer detection, risk assessment, and/or for distinguishing cancer from benign disease or aggressive from indolent cancers. The LBRLs will conduct research on the development of liquid biopsy technologies, assays and/or methods for the capture and analysis of tumor associated cells, DNA, RNA, or exosomes in body fluids of individuals with early-stage cancer or at high risk of developing the disease. Precompetitive alliances between academic and industry research teams must be integral to the LBRLs for more effective harmonization and successful validation of the developed liquid biopsy technologies, methods, and assays.

Deadline: 1/10/2023

Perception and Cognition Research to Inform Cancer Image Interpretation (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

Deadline: 2/5/2023

Building Research Capacity in Global Tobacco Product Regulation Program (U18) Clinical Trials Not Allowed

The Food and Drug Administration (FDA) announces its intention to accept and consider a single source application for award to the World Health Organization (WHO) for the Building Research Capacity in Global Tobacco Product Regulation Program. The purpose of the Program is to identify, support, develop, conduct, and coordinate research efforts relating to tobacco control laws and rules in foreign countries that will directly inform and support FDA’s exercise of its authority to regulate the manufacture, distribution, marketing and sale of tobacco products in the United States. The Program will advance FDA's Center for Tobacco Products' (CTP’s) mission by utilizing WHO Member States’ expertise and extensive international contacts in global tobacco control, as well as WHO's own programmatic expertise, to inform and support adequate manufacture, distribution and market regulations of tobacco products for the protection of public health in the United States.

Deadline: 1/16/2023

Proposals for waste management practices

The sustainability movement has reached the business models of nearly every industry in the United States, and many companies, municipalities and states have set aggressive sustainability goals that include how waste streams are being managed. The EREF Board of Directors has set an initiative to ensure research funded reflects EREF’s long-term strategic plan to address all areas of integrated solid waste management, with a strong focus towards research that increased sustainable solid waste management practices.

Deadline: 12/1/2022

Please contact your RAS unit *and* Nicole Dancz-Bal to inform them of your intent to submit.

Evidence for Action: Innovative Research to Advance Racial Equity

The Robert Wood Johnson Foundation (RWJF) is committed to building a national Culture of Health that enables all in our diverse society to lead healthier lives now and for generations to come. A Culture of Health is one in which good health and well-being flourish among all people, and everyone has the opportunity to lead a healthy lifestyle. Structural racism poses obstacles to achieving this ambitious goal by creating and upholding discriminatory systems, policies, and practices, many of which perpetuate health disparities by race, ethnicity, and other identities. 

Open Deadline

Please contact your RAS unit *and* Alison Thompson to inform them of your intent to submit.

Pioneering Ideas: Exploring the Future to Build a Culture of Health

As our current reality underscores, we live in a dynamic world—where unforeseen global events; new technologies; scientific discoveries; changes in our climate, economy, demographics; and more—continually shape where and how we live, learn, work and play. These changes will profoundly impact health equity in our society, from our individual health and the health of our families to the health of our communities.

Open Deadline

Please contact your RAS unit *and* Alison Thompson to inform them of your intent to submit.